New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug
This article was originally published in PharmAsia News
Executive Summary
New Zealand's Pharmac said the drug-coverage agency is weighing the $421,000-a-year cost against the benefits of subsidizing Alexion's Soliris (eculizumab) in treating to a rare type of hemophilia.